tnf-alpha , human

Mca-(endo-1a-Dap(Dnp))-TNF-Alpha (-5 to +6) amide (human) is a peptide used as a fluorescence resonance energy transfer (FRET) based substrate for proteolytic activity assays, with cleavage-induced changes in fluorescence intensity indicating enzymatic activity [1].

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

TNF-α (31-45), human acetate is a peptide of tumor necrosis factor-α.

Cot inhibitor-1 is a selective inhibitor of Cot protein kinase (also known as Tpl2 or MAP3K8) (IC50 at 28 nM). Cot inhibitor-1 inhibited TNF-alpha production in human whole blood with IC50 of 5.7 nM. Cot is involved in a variety of cellular signaling pathways, particularly those involved in inflammation and immune responses. Cot inactivate-1 inhibits Cot activity and may have potential therapeutic effects on rheumatoid arthritis, inflammatory bowel disease and some types of cancer.

TNF-α (31-45), human, is a peptide of tumor necrosis factor-α.

Rupatadine (UR-12592, rupatadine) is a potent and orally available dual antagonist of PAF and histamine H1 receptors with Ki values of 0.55 μM and 0.1 μM, respectively, which provides relief of allergic symptoms and anti-inflammatory properties, and is used in allergic rhinitis and chronic urticaria.

1. Ruscogenin has anti-inflammatory activity, suppressed zymosan A-evoked peritoneal total leukocyte migration in mice in a dose-dependent manner, 2. Ruscogenin inhibited adhesion of leukocytes to a human umbilical vein endothelial cell line (ECV34) injured by tumor necrosis factor-alpha (TNF-alpha) in a concentration-dependent manner. 3. Ruscogenin significantly attenuate LPS-induced acute lung injury via inhibiting expressions of TF and iNOS and NF-kappa B p65 activation.

TNF-α (31-45), human (TFA), is a peptide of tumor necrosis factor-α (TNF alpha), an inflammatory cytokine that induces necrosis or apoptosis.

3-Hydroxyxanthone (3-Hydroxy-xanthen-9-one), a xanthone derivative, inhibits NADPH-catalyzed lipid peroxidation in human umbilical vein endothelial cells (HUVECs) and suppresses TNF-alpha-induced ICAM-1 expression [1].

Onercept, a recombinant soluble form of the human tumor necrosis factor-alpha (TNF-α) p55 receptor, is utilized in the study of Crohn's disease [1].

ESBA-105 represents a highly stable, humanized single-chain Fv (scFv) antibody fragment specifically engineered to target and neutralize human tumor necrosis factor-alpha (TNF-α) with exceptional binding affinity. It effectively facilitates the measurable blockade of TNF-mediated pro-inflammatory signaling and apoptosis across various preclinical experimental models to evaluate the optimization of tissue penetration and pharmacokinetic stability during strictly monitored laboratory observation periods and functional neutralization assays.

Senlizumab is a human monoclonal antibody expressed in CHO cells that specifically targets TNFSF2 (Tumor Necrosis Factor-alpha, TNF-α). It features a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight of 146.9 kDa. Senlizumab neutralizes the biological activity of TNF-α by blocking its interaction with TNF receptors, thereby inhibiting downstream pro-inflammatory signaling pathways. It serves as a valuable tool for research into autoimmune and inflammatory diseases. The recommended isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).

Anti-TNF-alpha Antibody (5Z310) is a Mouse IgG1 monoclonal antibody targeting Human TNF-alpha.

Anti-TNF-alpha Antibody (9S740) is a Rabbit IgG monoclonal antibody targeting Human TNF-alpha.

Taxiresinol shows anticancer, antinociceptive, and antiallergic activities, it shows inhibitory activity on induced histamine release from the human basophilic cell line, KU812. Taxiresinol can protect the hepatocytes from apoptosis via an inhibition of TNF- alpha production by activated macrophages and a direct inhibition of apoptosis induced by TNF- alpha in D-GalN/LPS-treated mice.

Ruscogenin (Standard) is a reference standard for research and analysis in studies involving Ruscogenin. 1. Ruscogenin has anti-inflammatory activity, suppressed zymosan A-evoked peritoneal total leukocyte migration in mice in a dose-dependent manner, 2. Ruscogenin inhibited adhesion of leukocytes to a human umbilical vein endothelial cell line (ECV34) injured by tumor necrosis factor-alpha (TNF-alpha) in a concentration-dependent manner. 3. Ruscogenin significantly attenuate LPS-induced acute lung injury via inhibiting expressions of TF and iNOS and NF-kappa B p65 activation.

Glutinol acetate shows significant cytotoxic activity against four human cancer cell lines (HL-60, SK-OV-3, A549, and HT-29), with GI(50) in the range of 11.1-17.9microM; it also has anti-inflammatory effect, exhibits moderate inhibitory activity of TNF-alpha secretion in the lipopolysaccharide (LPS)-stimulated murine RAW264.7 macrophage cell line.

Bonducellin has anti-inflammatory activities, it can significantly and dose-dependently inhibit the inflammatory mediators; nitric oxide (NO), and cytokines [tumor necrosis factor (TNF)-alpha and interleukin (IL)-12. Bonducellin shows weak antimalarial ac

TNF-α (10-36), human (TFA) is a peptide of human TNF-α.

TNF-α (10-36), human, is a potent pro-inflammatory cytokine involved in the acute phase stress response.

Human TNF alpha (46-65) peptide.

TNF-α (31-45), human (TFA) is a peptide of tumor necrosis factor-α.

TNF-α (46-65), human (TFA) is a peptide of human TNF-α.